Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

abstract：:Progressive multifocal leukoencephalopathy (PML) is a rare and severe complication of natalizumab therapy in patients with multiple sclerosis and it may be accompanied by immune reconstitution inflammatory syndrome (IRIS). Here, we describe a case of abnormally severe IRIS, which occurred 2 months after natalizumab-as...

journal_title：Immunotherapy

authors： Calvi A,De Riz M,Pietroboni AM,Ghezzi L,Maltese V,Arighi A,Fumagalli GG,Jacini F,Donelli C,Comi G,Galimberti D,Scarpini E

更新日期：2014-01-01 00:00:00

abstract：:Aim: Autologous hematopoietic stem cell transplantation (ASCT) is the standard-of-care curative treatment for relapsed or refractory diffuse large B-cell lymphoma (RR-DLBCL), but the relapse rate is usually high. Materials & methods: In this study, we treated 14 RR-DLBCL patients by combining ASCT and anti-CD19 chimer...

journal_title：Immunotherapy

authors： Wang T,Gao L,Wang Y,Zhu W,Xu L,Wang Y,Yue W,Tang G,Chen L,Chen J,Zhang W,Yu X,Feng D,Yang J

更新日期：2020-09-01 00:00:00

abstract：:The rapid emergence of multidrug-resistant pathogens, especially Gram-negative bacteria and mycobacteria, represents one of the major medical challenges of the 21st century. The gradual loss of effective classical antibiotics for many bacterial pathogens, combined with an increasing population density and mobility, ur...

journal_title：Immunotherapy

authors： Helbig ET,Opitz B,Sander LE

更新日期：2013-04-01 00:00:00

abstract：:Brain tumors present unique therapeutic challenges and they include glioblastoma (GBM) and metastases from cancers of other organs. Current treatment options are limited and include surgical resection, radiation therapy, laser interstitial thermal therapy and chemotherapy. Although much research has been done on the d...

journal_title：Immunotherapy

authors： Liu Y,Chongsathidkiet P,Crawford BM,Odion R,Dechant CA,Kemeny HR,Cui X,Maccarini PF,Lascola CD,Fecci PE,Vo-Dinh T

更新日期：2019-10-01 00:00:00

abstract：:Immunotherapy strategies for cancer are focused on inducing effective and specific cytotoxic responses mediated by CD8 T cells. On the other hand, immunosuppressive mechanisms induced by the tumor, such as the generation of tumor-specific CD4(+)CD25(+)FoxP3(+) Tregs, conspire against the efficacy of immunotherapies. I...

journal_title：Immunotherapy

authors： Muccioli M,Longstaff C,Benencia F

更新日期：2012-05-01 00:00:00

abstract：:Therapeutic vaccination with dendritic cells (DCs) is recognized as an important experimental therapy for the treatment of minimal residual disease in acute myeloid leukemia. Many sources of leukemia-associated antigens and different methods for antigen loading of DCs have been used in an attempt to optimize anti-tumo...

journal_title：Immunotherapy

authors： van den Ancker W,van Luijn MM,Westers TM,Bontkes HJ,Ruben JM,de Gruijl TD,Ossenkoppele GJ,van de Loosdrecht AA

更新日期：2010-01-01 00:00:00

abstract：:John L Stanford speaks to Hannah Wilson, Assistant Commissioning Editor John L Stanford is Chief Scientific Officer at BioEos Ltd (Kent, UK). Dr Stanford began his career as a senior lecturer and then reader in microbiology at Middlesex Hospital Medical School (London, UK), then University College London Medical Schoo...

journal_title：Immunotherapy

authors： Stanford JL

更新日期：2013-05-01 00:00:00

abstract：:Over the last few years, extensive research has improved our understanding of tumor immunology and has enabled the development of novel treatments. The state of the art of immunotherapy in various types of malignancies was exhaustively discussed in the 'Immunotherapy Bridge' meeting, which was held in Naples on 4-5 De...

journal_title：Immunotherapy

authors： Ascierto PA,Garbe C

更新日期：2020-02-01 00:00:00

abstract：:Despite novel chemotherapy treatments, pancreatic ductal adenocarcinoma (PDA) remains a lethal disease. New targeted cancer vaccines may represent a viable option for patients with PDA. The Wilms' tumor 1 (WT1) antigen is one of the most widely expressed tumor-associated antigens in various types of tumors, including ...

journal_title：Immunotherapy

authors： Koido S,Okamoto M,Shimodaira S,Sugiyama H

更新日期：2016-11-01 00:00:00

abstract：:Melanoma antigen family A, 3 (MAGE-A3) is a cancer-testis antigen whose expression has been demonstrated in a wide array of malignancies including melanoma, brain, breast, lung and ovarian cancer. In addition, its ability to elicit spontaneous humoral and cellular immune responses has been shown in cancer patients. As...

journal_title：Immunotherapy

authors： Esfandiary A,Ghafouri-Fard S

更新日期：2015-01-01 00:00:00

abstract：:There has been a surge in the use of immunotherapy for genitourinary malignancies. Immunotherapy is an established treatment for metastatic renal cell carcinoma and nonmuscle invasive bladder cancer, but its potential for treating prostate cancer (PCa) remains under investigation. Despite reported survival benefits, n...

journal_title：Immunotherapy

authors： Sathianathen NJ,Krishna S,Konety BR,Griffith TS

更新日期：2017-09-01 00:00:00

abstract：:Meningiomas are increasingly appreciated to share similar features with other intra-axial central nervous system neoplasms as well as systemic cancers. Immune checkpoint inhibition has emerged as a promising therapy in a number of cancers, with durable responses of years in a subset of patients. Several lines of evide...

journal_title：Immunotherapy

authors： Bi WL,Wu WW,Santagata S,Reardon DA,Dunn IF

更新日期：2016-06-01 00:00:00

abstract：AIM:Few studies have compared cluster immunotherapy and conventional administration regimens. The aim of this study was to establish the safety profile of these different regimens in patients with allergic respiratory diseases who received index-of-reactivity (IR)-standardized allergen extracts by the subcutaneous rout...

journal_title：Immunotherapy

authors： Quiralte J,Justicia JL,Cardona V,Dávila I,Moreno E,Ruiz B,García MA

更新日期：2013-12-01 00:00:00

abstract：:Achieving long-term control of colorectal cancers with therapeutic vaccines that generate potent anti-tumor T cell and antibody responses has been a goal for more than two decades. To date, clinical trials of these vaccines have demonstrated induction of immune responses, but clinical benefit has been limited. Improve...

journal_title：Immunotherapy

authors： Patel SP,Osada T,Lyerly HK,Morse MA

更新日期：2014-01-01 00:00:00

abstract：AIMS:A therapeutic vaccine based on monocyte-derived dendritic cells (MDDCs) has been shown to represent a promising strategy for the treatment of cancer and viral infections. Here, we characterized the MDDCs used as an immunogen in a clinical trial for an anti-HIV-1 therapeutic vaccine. PATIENTS & METHODS:Monocytes o...

journal_title：Immunotherapy

authors： da Silva LT,da Silva WC,de Almeida A,da Silva Reis D,Santillo BT,Rigato PO,da Silva Duarte AJ,Oshiro TM

更新日期：2018-08-01 00:00:00

abstract：:The poor prognosis of pancreatic cancer patients signifies a need for radically new therapeutic strategies. Tumor-targeted oncolytic viruses have emerged as attractive therapeutic candidates for cancer treatment due to their inherent ability to specifically target and lyse tumor cells as well as induce antitumor effec...

journal_title：Immunotherapy

authors： Al Yaghchi C,Zhang Z,Alusi G,Lemoine NR,Wang Y

更新日期：2015-01-01 00:00:00

abstract：:Aim: Assessment of safety, tolerability and changes in global clinical impression with an multiallergen immunotherapy treatment without dilutional effect in polyallergic patients. Patients & methods: This observational prospective study included patients with allergic rhinitis-rhinoconjunctivitis with or without asthm...

journal_title：Immunotherapy

authors： Alba P,Moreno V,Arias-Irigoyen J,Antón M,Parra A,Gómez-Fernández MC,Madariaga B,Martínez A,Begoña L

更新日期：2020-01-01 00:00:00

abstract：:Immunotherapy holds a highly promising treatment approach for metastatic melanoma patients. Adoptive cell transfer (ACT) involves the ex vivo expansion of autologous antitumor reactive lymphocytes and their reinfusion into lymphodepleted patients, accompanied by IL-2 administration. ACT with tumor-infiltrating T lymph...

journal_title：Immunotherapy

authors： Itzhaki O,Levy D,Zikich D,Treves AJ,Markel G,Schachter J,Besser MJ

更新日期：2013-01-01 00:00:00

abstract：AIM:Previous studies showed that some patients after the treatment of anti-programmed cell death protein-1 (anti-PD-1) antibodies experienced immune-related diarrhea. In this study, we aim to explore the association between intestinal microbiota and immune-related diarrhea. METHODS:We obtained the fecal samples of 26 ...

journal_title：Immunotherapy

authors： Liu T,Xiong Q,Li L,Hu Y

更新日期：2019-04-01 00:00:00

abstract：:HER2/neu is expressed in the majority of in situ breast cancers, but maintained in 20-30% of invasive breast cancer (IBC). During breast tumorigenesis, there is a progressive loss of anti-HER2 CD4(pos) Th1 (anti-HER2Th1) from benign to ductal carcinoma in situ, with almost complete loss in IBC. This anti-HER2Th1 respo...

journal_title：Immunotherapy

authors： De La Cruz LM,Nocera NF,Czerniecki BJ

更新日期：2016-10-01 00:00:00

abstract：:Antibodies and antibody-based therapeutics have become big business, with annual sales over US$50 billion, accounting for >6% of worldwide pharmaceutical revenues. Ten molecules have blockbuster status (>US$1 billion), with six generating more than US$6 billion in sales. In excess of 300 products based on this rapidly...

journal_title：Immunotherapy

authors： Larrick JW

更新日期：2012-03-01 00:00:00

abstract：:Activation of a patient's immune system offers an attractive approach to prevent and treat hepatocellular carcinoma (HCC). However, the antitumor efficacy of current HCC vaccines was weak owing to insufficient immune activation of targeting self/tumor antigens. We recently found that epitope-optimized α-fetoprotein ef...

journal_title：Immunotherapy

authors： He Y,Hong Y,Mizejewski GJ

更新日期：2014-01-01 00:00:00

abstract：AIM:This study assessed the safety of Polyoxidonium® 6 mg lyophilisate for solution for injection in routine practice with a special focus on signs or symptoms of potential adverse renal effects. MATERIALS & METHODS:A local, multicenter, prospective, open-label, noninterventional, uncontrolled postauthorization safety...

journal_title：Immunotherapy

authors： Pružinec P,Chirun N,Sveikata A

更新日期：2018-02-01 00:00:00

abstract：:FOCIS goes South: Advances in Translational and Clinical Immunology was the first Federation of Clinical Immunology Societies (FOCIS) ( www.focisnet.org ) meeting held in Latin America (May 15-17, 2017, Santiago de Chile, Chile). The meeting was organized as a 3-day workshop and was fostered by the Millennium Institut...

journal_title：Immunotherapy

authors： Kalergis AM,Anegon I,González PA

更新日期：2017-09-01 00:00:00

abstract：:In spite of the considerable successes that have been achieved in the treatment of chronic myeloid leukemia (CML), cure for the disease can only be obtained by the present means in a rather small minority of patients. During the past decade, considerable progress has been made in the understanding of the immunology of...

journal_title：Immunotherapy

authors： Vonka V

更新日期：2010-03-01 00:00:00

abstract：AIM:This meta-analysis aims at assessing the correlation of PD-L1 levels and response PD-1/PD-L1 inhibitors in advanced malignant melanoma. METHODS:Eligible studies included those evaluating PD-1/PD-L1 inhibitors in advanced melanoma and correlating the outcomes to PD-L1 levels. RESULTS:After preclusion of ineligible...

journal_title：Immunotherapy

authors： Abdel-Rahman O

更新日期：2016-09-01 00:00:00

abstract：:Mycobacterium bovis bacille Calmette-Guerin (BCG) is one of the great success stories of immunotherapy as a treatment for superficial urothelial carcinoma of the bladder. Despite clinical effectiveness in over 50% of patients, the high incidence of local side effects and presence of nonresponders has led to efforts to...

journal_title：Immunotherapy

authors： Kresowik TP,Griffith TS

更新日期：2009-03-01 00:00:00

abstract：:Evaluation of: Pujol-Autonell I, Ampudia RM, Monge P et al. Immunotherapy with tolerogenic dendritic cells alone or in combination with rapamycin does not reverse diabetes in NOD mice. ISRN Endocrinol. doi:10.1155/2013/346987 (2013) (Epub ahead of print). Many reports confirm that dendritic cells (DCs) can prevent aut...

journal_title：Immunotherapy

authors： Giannoukakis N

更新日期：2013-06-01 00:00:00

abstract：:Evaluation of: Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121(5), 1822-1826 (2011). Chimeric antigen receptor (CAR)-T cells are promising antitumor immunotherapies. However, there are limit...

journal_title：Immunotherapy

authors： Gandhi M,Jones K

更新日期：2011-12-01 00:00:00

abstract：:Waldenström macroglobulinemia (WM) is a lymphoproliferative lymphoma that is characterized by monoclonal immunoglobulin M (IgM) protein and bone marrow infiltration. Its incidence is rare and rarer still is its ability to transform to a B-cell lymphoma, particularly the aggressive diffuse large B-cell lymphoma, which ...

journal_title：Immunotherapy

authors： Okolo ON,Johnson AC,Yun S,Arnold SJ,Anwer F

更新日期：2017-08-01 00:00:00